Evidence map›Paper›PMID 29555916›Full record

ArticleScientific reports2018

Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals.

Montserrat Baldan-Martin, Juan A Lopez, Nerea Corbacho-Alonso, Paula J Martinez, Elena Rodriguez-Sanchez, Laura Mourino-Alvarez, Tamara Sastre-Oliva, Tatiana Martin-Rojas, Raul Rincón, Eva Calvo and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Montserrat Baldan-MartinDepartment of Vascular Physiopathology, Hospital Nacional de Paraplejicos (HNP), SESCAM, Toledo, Spain.
Juan A LopezCardiovascular Proteomics Laboratory and CIBER-CV, CNIC, Madrid, Spain.
Nerea Corbacho-AlonsoDepartment of Vascular Physiopathology, Hospital Nacional de Paraplejicos (HNP), SESCAM, Toledo, Spain.
Paula J MartinezDepartament of Immunology, IIS-Fundacion Jimenez Diaz, Madrid, Spain.
Elena Rodriguez-SanchezLaboratory of Hypertension and Cardiovascular Risk, Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, Madrid, Spain.
Laura Mourino-AlvarezDepartment of Vascular Physiopathology, Hospital Nacional de Paraplejicos (HNP), SESCAM, Toledo, Spain.
Tamara Sastre-OlivaDepartment of Vascular Physiopathology, Hospital Nacional de Paraplejicos (HNP), SESCAM, Toledo, Spain.
Tatiana Martin-RojasDepartment of Vascular Physiopathology, Hospital Nacional de Paraplejicos (HNP), SESCAM, Toledo, Spain.
Raul RincónDepartment of Vascular Physiopathology, Hospital Nacional de Paraplejicos (HNP), SESCAM, Toledo, Spain.
Eva CalvoIbermutuamur, Madrid, Spain.
Jesus VazquezCardiovascular Proteomics Laboratory and CIBER-CV, CNIC, Madrid, Spain.
Fernando VivancoDepartament of Immunology, IIS-Fundacion Jimenez Diaz, Madrid, Spain.
Luis R PadialDepartamento de Cardiologia, Complejo Hospitalario de Toledo, SESCAM, Toledo, Spain.
Gloria Alvarez-LlamasDepartament of Immunology, IIS-Fundacion Jimenez Diaz, Madrid, Spain.
Gema Ruiz-HurtadoLaboratory of Hypertension and Cardiovascular Risk, Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, Madrid, Spain.
Luis M RuilopeLaboratory of Hypertension and Cardiovascular Risk, Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, Madrid, Spain. ruilope@icloud.com.
Maria G BarderasDepartment of Vascular Physiopathology, Hospital Nacional de Paraplejicos (HNP), SESCAM, Toledo, Spain. megonzalezb@sescam.jccm.es.
Hospital Nacional de Parapléjicos · ESHospital Universitario Fundación Jiménez Díaz · ESCentro de Investigación en Red en Enfermedades Cardiovasculares · ESServicio de Salud de Castilla La Mancha · ESUniversidad Europea de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The evaluation of cardiovascular (CV) risk is based on equations derived from epidemiological data in individuals beyond the limits of middle age such as the Framingham and SCORE risk assessments. Lifetime Risk calculator (QRisk

Indexed as

AdultBiomarkersCardiovascular DiseasesCardiovascular SystemFemaleHumansMaleMiddle AgedProteomicsRisk AssessmentRisk FactorsBiomarkers

Identifiers

PMID29555916
PMCPMC5859270
OpenAlexW2801099391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.